==See also==
==See also==
* [[4-HO-DsBT]]
* [[Substituted tryptamine]]
* [[Substituted tryptamine]]
* [[Disecbutyltryptamine|DsBT]] and [[4-HO-DsBT]]
==References==
==References==
Pharmaceutical compound
 |
|
| Clinical data | |
|---|---|
| Other names | 5-MeO-DSBT; 5-Methoxy-N,N-di-sec-butyltryptamine |
| ATC code | |
| Identifiers | |
|
|
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H30N2O |
| Molar mass | 302.462 g·mol−1 |
| 3D model (JSmol) | |
|
|
|
|
5-MeO-DsBT, also known as 5-methoxy-N,N-di-sec-butyltryptamine, is a chemical compound and possible psychedelic drug of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT.[1] It was briefly mentioned by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] He described it as being an unknown compound.[1] Relatedly, its route, dose, and duration were not described.[1] 5-MeO-DsBT was first described in the literature by Shulgin in TiHKAL in 1997.[1] It is a skeletal isomer of 5-MeO-DBT.[1] Subsequently, close analogues of 5-MeO-DsBT like 5-MeO-MsBT and 5-MeO-NsBT emerged as novel designer drugs in the early 2020s.[2][3][4] 5-MeO-DsBT is not a controlled substance in Canada as of 2025.[5]
- ^ a b c d e f
Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
- ^ “5-MeO-MsBT (5-methoxy-N-methyl-N-secbutyltryptamine)”. AIPSIN (in Russian). Retrieved 2 January 2026.
- ^ “5-MeO-NsBT (5-MeO-N-secbutyltryptamine)”. АИПСИН (in Russian). Retrieved 6 January 2026.
- ^ Yurchenko R, Yurchenko L, Pavlovets Y, Galetskaya I (January 2023). “Recent trends in the identification of psychoactive substances”. AIPSIN Belarusian Monitoring Platform (in Russian) (37). doi:10.13140/RG.2.2.34396.46722. Retrieved 2 January 2026.
- ^ “Controlled Drugs and Substances Act”. Department of Justice Canada. Retrieved 19 January 2026.
